Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators

Bioconjugate Chemistry

Volumn 17, Issue 6, 2006, Pages 1551-1560

  Antczak, Christophe ^a   Jaggi, Jaspreet S ^a   LeFave, Clare V ^a   Curcio, Michael J ^a   McDevitt, Michael R ^a   Scheinberg, David A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Box 531   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CHELATION; ISOTOPES; MAMMALS; METABOLISM; RADIOACTIVITY; TUMORS;

ANTIBODY-TARGETED; BIFUNCTIONAL CHELATING AGENT; BIODISTRIBUTIONS; CONDITION; CURRENT LIMITATION; IN-VIVO; MALEIMIDES; MICE LIVER; RADIOIMMUNOCONJUGATES; SELF-IMMOLATIVE;

MONOCLONAL ANTIBODIES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 [4 (2 MERCAPTOETHYLTHIOUREIDO)BENZYL (1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)]; 3 MERCAPTO 2 [3 PHENYL 2 [2 [2 [2 [3 [2 [4 (1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)]BENZYL]THIOUREIDO]ACETYLAMINO]ACETYLAMINO]ACETYLAMINO]PROPIONYLAMINO]PROPIONIC ACID; ACTINIUM 225; ANTIBODY CONJUGATE; CATHEPSIN B; CHELATING AGENT; MALEIMIDE; MONOCLONAL ANTIBODY; THIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATABOLISM; CELL STRAIN HL 60; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; TISSUE DISTRIBUTION;

EID: 33845205546     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060156+     Document Type: Article

References (52)

1. Scheinberg, D. A., Tanimoto, M., McKenzie, S., Strife, A., Old, L. J., and Clarkson, B. D. (1989) Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 3, 440-5.
2. Tanimoto, M., Scheinberg, D. A., Cordon-Cardo, C., Huie, D., Clarkson, B. D., and Old, L. J. (1989) Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 3, 339-48.
3. Bernstein, I. D., Singer, J. W., Andrews, R. G., Keating, A., Powell, J. S., Bjomson, B. H., Cuttner, J., Najfeld, V., Reaman, G., Raskind, W.; Sutton, D. M. C., and Fialkow, P. J. (1987) Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J. Clin. Invest. 79, 1153-9.
4. Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., and Schlossman, S. F. (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. 8, 521-34.
5. Co, M. S., Avdalovic, N. M., Caron, P. C., Avdalovic, M. V., Scheinberg, D. A., and Queen, C. (1992) Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148, 1149-54.
6. Scheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Feirt, N., Finn, R. D., Clarkson, B. D., Gee, T. S., Larson, S. M., Octtgen, H. F., and Old, L. J. (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. 9, 478-90.
7. Scheinberg, D. A., and Strand, M. (1982) Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res. 42, 44-9.
8. Scheinberg, D. A., and Strand, M. (1983) Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res. 43, 265-72.
9. Scheinberg, D. A., Strand, M., and Gansow, O. A. (1982) Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 215, 1511-3.
10. Geerlings, M. W., Kaspersen, F. M., Apostolidis, C., and van der Hout, R. (1993) The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl. Med. Commun. 14, 121-5.
11. Kaspersen, F. M., Bos, E., Doornmalen, A. V., Geerlings, M. W., Apostolidis, C., and Molinet, R. (1995) Cytotoxicity of 213Bi- and 225Ac-immunoconjugates. Nucl. Med. Commun. 16, 468-76.
12. Macklis, R. M., Lin, J. Y., Beresford, B., Atcher, R. W., Hines, J. J., and Humm, J. L. (1992) Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat. Res. 130, 220-6.
13. Vriesendorp, H. M., Quadri, S. M., Andersson, B. S., and Dicke, K. A. (1996) Hematologic side effects of radiolabeled immunoglobulin therapy. Exp. Hematol. 24, 1183-90.
14. McDevitt, M. R., Barendswaard, E., Ma, D., Lai, L., Curcio, M. J., Sgouros, G., Ballangrud, A. M., Yang, W. H., Finn, R. D., Pellegrini, V., Geerlings, M. W., Jr., Lee, M., Brechbiel, M. W., Bander, N. H., Cordon-Cardo, C., and Scheinberg, D. A. (2000) An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-100.
15. McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., Bander, N. H., and Scheinberg, D. A. (2001) Tumor therapy with targeted atomic nanogenerators, Science 294, 1537-40.
16. Zalutsky, M. R., and Vaidyanathan, G. (2000) Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr. Pharm. Des. 6, 1433-55.
17. Borchardt, P. E., Yuan, R. R., Miederer, M., McDevitt, M. R., and Scheinberg, D. A. (2003) Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63, 5084-90.
18. Miederer, M., McDevitt, M. R., Borchardt, P., Bergman, I., Kramer, K., Cheung, N. K., and Scheinberg, D. A. (2004) Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialoganglioside GD2. Clin. Cancer Res. 10, 6985-92.
19. McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., and Scheinberg, D. A. (2002) Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl. Radiat. Isot. 57, 841-7.
20. Andrew, S. M., Perkins, A. C., Pimm, M. V., and Baldwin, R. W. (1988) A comparison of iodine and indium labelled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts. Eur. J. Nucl Med. 13, 598-604.
21. Pimm, M. V., Perkins, A. C., and Baldwin, R. W. (1985) Differences in tumour and normal tissue concentrations of iodine-and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts. Eur. J. Nucl. Med. 11, 300-4.
22. Jaggi, J. S., Seshan, S. V., McDevitt, M. R., LaPerle, K., Sgouros, G., and Scheinberg, D. A. (2005) Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J. Am. Soc. Nephrol. 16, 2677-89.
23. Kukis, D. L., Novak-Hofer, I., and DeNardo, S. J. (2001) Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother. Radiopharm. 16, 457-67.
24. Quadri, S. M., and Vriesendorp, H. M. (1998) Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Q. J. Nucl. Med. 42, 250-61.
25. Wu, A. M., and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-46.
26. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M., Doronina, S. O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-52.
27. Sutherland, M. S., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., Senter, P. D., Law, C. L., and Wahl, A. F. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281, 10540-7.
28. Berquin, I. M., and Sloane, B. F. (1996) Cathepsin B expression in human tumors. Adv. Exp. Med. Biol. 389, 281-94.
29. DeNardo, G. L., DeNardo, S. J., Peterson, J. J., Miers, L. A., Lam, K. S., Hartmann-Siantar, C., and Lamborn, K. R. (2003) Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin. Cancer Res. 9, 3865S-72S.
30. DeNardo, G. L., Kroger, L. A., Meares, C. F., Richman, C. M., Salako, Q., Shen, S., Lamborn, K. R., Peterson, J. J., Miers, L. A., Zhong, G. R., and DeNardo, S. J. (1998) Comparison of 1,4,7,10-tetraazacyclododecane-N,N′, N″,N‴-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]- DOTA-ChL6 in breast cancer xenografts. Clin. Cancer Res. 4, 2483-90.
31. DeNardo, S. J., DeNardo, G. L., Yuan, A., Richman, C. M., O'Donnell, R. T., Lara, P. N., Kukis, D. L., Natarajan, A., Lamborn, K. R., Jacobs, F., and Siantar, C. L. (2003) Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N′,N′,N‴-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin. Cancer Res. 9, 3938S-44S.
32. Richman, C. M., Denardo, S. J., O'Donnell, R. T., Yuan, A., Shen, S., Goldstein, D. S., Tuscano, J. M., Wun, T., Chew, H. K., Lara, P. N., Kukis, D. L., Natarajan, A., Meares, C. F., Lamborn, K. R., and DeNardo, G. L. (2005) High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11, 5920-7.
33. 212Pb(DOTA)2-. Radiochim. Acta 60, 1-10.
34. Barrett, A. J., and Kirschke, H. (1981) Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol. 80, 535-61.
35. Li, M., and Meares, C. F. (1993) Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjugate Chem. 4, 275-83.
36. Geissler, F., Anderson, S. K., and Press, O. (1991) Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell. Immunol. 137, 96-110.
37. Geissler, F., Anderson, S. K., Venkatesan, P., and Press, O. (1992) Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 52, 2907-15.
38. Jones, P. L., Brown, B. A., and Sands, H. (1990) Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver. Cancer Res. 50, 852s-856s.
39. Duncan, J. R., and Welch, M. J. (1993) Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J. Nucl. Med. 34, 1728-38.
40. Franano, F. N., Edwards, W. B., Welch, M. J., and Duncan, J. R. (1994) Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-epsilon-lysine as the primary metabolic and excretory product. Nucl. Med. Biol. 21, 1023-34.
41. Rogers, B. E., Franano, F. N., Duncan, J. R., Edwards, W. B., Anderson, C. J., Connett, J. M., and Welch, M. J. (1995) Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 55, 5714s-5720s.
42. Novak-Hofer, I., Zimmermann, K., and Schubiger, P. A. (2001) Peptide linkers lead to modification of liver metabolism and improved tumor targeting of copper-67-labeled antibody fragments. Cancer Biother. Radiopharm. 16, 469-81.
43. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F., and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 17, 114-24.
44. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun. M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-70.
45. Khawli, L. A., Glasky, M. S., Alauddin, M. M., and Epstein, A. L. (1996) Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. Cancer Biother. Radiopharm. 11, 203-15.
46. Kim, I., Kobayashi, H., Yoo, T. M., Kim, M. K., Le, N., Han, E. S., Wang, Q. C., Pastan, I., Carrasquillo, J. A., and Paik, C. H. (2002) Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents. Nucl. Med. Biol. 29, 795-801.
47. Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J. E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., and Carrasquillo, J. A. (1999) The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Ren. 59, 422-30.
48. Ohkuma, S. (1987) The lysosomal proton pump. In Lysosomes: Their Role in Protein Breakdown (Glaumann, H., and Ballard, F., Eds.), Academic Press, New York.
49. Trouet, A., Masquelier, M., Baurain, R., and Deprez-De Campeneere, D. (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 79, 626-9.
50. Studer, M., Kroger, L. A., DeNardo, S. J., Kukis, D. L., and Meares, C. F. (1992) Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo. Bioconjugate Chem. 3, 424-9.
51. Peterson, J. J., Pak, R. H., and Meares, C. F. (1999) Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid-functionalized peptides for radioimmunotherapy. Bioconjugate Chem. 10, 316-20.
52. Peterson, J. J., and Meares, C. F. (1999) Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Bioconjugate Chem. 10, 553-7.